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Abstract
Background: Early graft dysfunction due to preservation/reperfusion injury represents a dramatic event after liver
transplantation. Enhancement of donor organ criteria, in order to cope with the ever increasing donor shortage,
further increases graft susceptibility to ischemic alterations.
Major parts of post-preservation injury, however, occur at the time of warm reperfusion but not during ischemic
storage; successful reperfusion of ischemic tissue in turn depends on an adequate redox and intracellular signal
homeostasis. The latter has been shown experimentally to be favorably influenced by oxygen persufflation within
short time spans. Thus viability of marginally preserved liver grafts could still be augmented by transient
hypothermic reconditioning even after normal procurement and static cold storage. The present study is aimed to
confirm the conceptual expectations, that hypothermic reconditioning by gaseous oxygen persufflation is a useful
method to suppress injurious cellular activation cascades and to improve post-ischemic recovery of marginally
preserved liver grafts.
Methods/Design: OPAL is a prospective single center randomized proof of concept study, including two parallel
groups in a total of 116 liver transplant patients. The effect of an in hospital treatment of the isolated liver graft by
2 hours of oxygen persufflation immediately prior to transplantation will be assesses as compared to standard
procedure (cold storage without further intervention). The primary endpoint is the peak transaminase serum level
(AST) during the first three days after transplantation as a surrogate readout for parenchymal liver injury. Other
outcomes comprise patient and graft survival, time of intensive care requirement, hepatic tissue perfusion 1h after
revascularisation, early onset of graft dysfunction based on coagulation parameters, as well as the use of a refined
scoring-system for initial graft function based on a multi-parameter (AST, ALT, Quick and bilirubin) score.
Furthermore, the effect of OPAL on molecular pathways of autophagy and inflammatory cell activation will be
evaluated. Final analysis will be based on all participants as randomized (intention to treat).
Trial Registration: Current Controlled Trials ISRCTN00167887
Background
Early graft dysfunction due to preservation/reperfusion
injury represents a dramatic event after liver transplan-
tation, affecting long term prognosis of graft viability
and patient outcome [1,2].
In face of the growing shortage of donor organs, the
acceptance criteria for liver retrieval have been expanded
torwards the inclusion of of older donors and the use of
‘less than optimal’ organs. In doing so, the increased pro-
clivity of these organs to ischemia and cold preservation
enhances the risk of primary dys- or even non-function
(PNF) of the liver after transplantation. While the num-
ber of donors aging > 65 years has increase more than
ten-fold from 1991 to 2001 in the United Network for
Organ sharing as well as the European Liver Transplant
registry [3], increased donor age has been incriminated in
large series as a prominent factor associated with
decreased graft survival [4,5]. A multivariate analysis of
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1148 donor livers showed significantly decrease 3 year
survival (62%) in livers originating from donors of > 65
years compared to 75% standard criteria donor grafts [6].
Likewise, moderate to severe degrees of fat accumulation,
which was present in 12% of all donor livers, was found
an independent predictor of increased preservation injury
[4]. Thus the challenges rise concerning maintenance
and/or restoration of tissue integrity during the storage
period.
An elegant means to do so lies in the provision of oxygen
during storage using gaseous oxygen application through
the vascular system. The method of venous systemic oxy-
gen persufflation [7] is a simple and versatile way to regen-
erate cellular energy dependent pathways under conditions
of relatively low metabolic work load. Any improvement in
the preservation of grafts, which were procured from
extended criteria donors and/or experienced extended
times of preservation represent a valuable advance to
enlarge the total number of viable donor organs and to cir-
cumvent the need of re-transplantation.
Earlier experimental studies have suggested that major
parts of the post preservation injury occur at the time of
warm reperfusion but not during ischemic storage and
that deleterious priming of the graft during ischemia
can be abrogated prior to transplantation by dynamic
revitalization techniques at the end of cold storage [8,9],
even in liver grafts which were donated after cardiac
death [10].
Since successful reperfusion of ischemic tissue most
likely depends on an adequate redox and intracellular
signal homeostasis, which is favorably influenced by oxy-
gen persufflation within short time spans, viability of
long preserved liver grafts is improved by transient
hypothermic reconditioning (HR) prior to implantation.
The optimal treatment time for hypothermic recondi-
tioning of initially cold stored livers by gaseous oxygen
persufflation has previously been investigated in a precli-
nical large animal model. One hour of HR already nota-
bly improved functional outcome upon reperfusion, but
the maximal therapeutic effect was obtained after 2
hours [11]. Thus, 2 hours of end-ischemic oxygen per-
sufflation of cold stored porcine livers significantly
improved survival after transplantation [12].
The technique of vascular oxygen persufflation not
only maintains cell and organ integrity and function but
also enables (to some extend) the repair of damaged
structures and restoration of cellular ion and signal
homeostasis.
Moreover, it has shown to reverse ischemia induced
breakdown of cellular autophagy [13], thus restoring the
cell’s regenerative capacity upon reperfusion to remove
damaged organelles and recycle denaturated proteins
[14,15].
Owing to its simplicity and ease of application, oxygen
persufflation appears to be a particularly convenient
approach, already shown to be safe and easily applicable
to the human situation [16].
Based on these promising results, the present clinical
trial protocol was designed as a final Proof-of-Concept
study aiming to establish oxygen persufflation as valu-
able adjunct in clinical liver preservation.
Methods/Design
This is a single center, randomized, controlled, single
blind clinical Proof-of Concept study.
Using a two parallel arms approach (treatment/control)
the question will be addressed whether a hypothermic
reconditioning protocol using 2h of gaseous oxygen per-
sufflation of the isolated liver graft immediately prior to
transplantation will improve early graft function upon
reperfusion and mitigate adverse effects associated with
preservation/reperfusion injury as compared to standard
care (simple cold storage without further intervention).
Only patients who meet all inclusion/exclusion criteria
are considered to be included in the trial. The inclusion
criteria are:
• Men and women beyond 18 years of age
• Resident in Germany
• Scheduled for first liver transplantation and graft
already available
• Patient is willing and able to attend regular follow
up examinations
• Written informed consent
Inclusion criteria for the donor liver
• Donor grafts that are offered to the local Transplant
clinic for Implantation, i.e. ‘organ rescue offers’, or
donor age above 65
Main exclusion criteria
Patients presenting with any of the following are not
included in the trial:
• Listed as high urgency (HU)
• Participation in this study at an earlier time
• Simultaneous participation in other clinical trial
• Positive test for HIV
• Pregnant or nursing
All patients are observed for seven days following
transplantation on a daily basis. Follow up includes addi-
tional observations on the day of discharge and 3 month
after transplantation. Patients are followed until 3 month
after the last patient is randomized for this trial and are
asked to attend clinical routine follow up subsequent to
termination of the study.
The schedule for study related activities and data col-
lection is listed in table 1.
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Objectives and endpoints
It is the aim of the present study to demonstrate the
efficacy of short-term oxygen persufflation as end-
ischemic adjunct in liver preservation to improve early
graft recovery after transplantation.
Serum peaks of liver transaminases are expected to be
surrogates of the extent of reperfusion injury and repre-
sent the most commonly used parameters for the progres-
sion of liver related disease. They correlate well with
parenchymal graft injury [17], usually associated with
initial liver dysfunction after transplantation in clinical stu-
dies [4,18]. Therefore the peak value of systemic aspartate
aminotransferase (AST) during the first three days after
transplantation has been chosen as the most important
primary endpoint of this study. In considering the serum
levels during a period of three days it is thought that a
more solid basis will be obtained for the judgment of the
individual liver under investigation and to alleviate possi-
ble skews of single measurements.
Secondary outcomes are death and retransplantation (3
month mortality) as well as time of ICU-stay, time of ven-
tilation and haemodialysis, complication rate, hepatic tis-
sue perfusion 1h after revasularisation, early onset of graft
dysfunction based on Quick’s value, as well as the use of a
refined scoring-system for initial graft function based on a
multi-parameter (AST, ALT, Quick and bilirubin) score
according to Heise and co-workers [19].
Moreover, pathophysiological, molecular analyses will be
performed as to investigate the impact of hypothermic
reconditioning on hepatocellular autophagy [13,20] and
early pro-inflammatory surface activation (ICAM-1, TLR
expression) after reperfusion.
Sample size calculation
The sample size calculation is performed for the primary
endpoint (maximum absolute AST value during the first
three days after transplantation) which is analyzed by an
exact two-sided Mann-Whitney-U-test. Under the null
hypothesis we expect no differences of the primary end-
point distributions for the two groups which translates
into a relative effect p = 0.5, i.e. it is similarly likely to
observe larger/smaller maximum AST values under one
or the other group condition. Under the alternative
hypotheses larger maximum AST values are on average
expected for the standard treatment. For a significance
level a = 0.05 (two-sided) and 52 patients per group
would be necessary for a power of 0.8 to detect a relative
effect of p = 0.66 (which is comparable to a mean differ-
ence of ~0.6 in units of standard deviations of a standard
normal distribution if a parametric location shift (t-test)
model would be appropriate). Considering a drop out
rate of 10%, 58 patients per group (overall 116 patients)
will be required.
Randomization and treatment
The randomization will be a stratified 1:1 stratified block
randomization with blocks of variable block length with
patient-level stratification factor Model for End-Stage
Liver Disease (MELD) score (three levels: < 20, 20-30 und
> 30). The donor liver is randomized by our study design.
Only patients who had given informed consent to partici-
pate in the study will be included in the randomization
and the study.
Randomization will be technically realized by a web-
interface as organized by the Center for Clinical Trials
Essen (ZKSE) who will also train the staff in running
the software. Moreover, the ZKSE will monitor and con-
trol the randomization.
Treatment is restricted to the isolated liver graft after
arrival in the transplantation clinic. In the treatment
group, donor livers arriving at the hospital will be sub-
jected to 2 hours of venous systemic oxygen persufflation
Table 1 Flow chart
screening waiting-
phase




D3 D3 D4 D5 D6 discharge
Informed consent X




BQS/complications X X X X
Postoperative dialysis X X X X X X X X
Time of mechanical ventilation X X X X X X X X
Laboratory parameters X X X X X X X X X X X
SAE X X X X X X X X X X
Death X X X X X X X X X X
Retransplantation X X X X X X X X X
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(OP) prior to implantation, while still being stored in ice
cold preservation solution as described previously
[7,16,21].
In brief, medical grade oxygen gas is passed through a
wash bottle and filtered through a membrane with pore
size of 5 μm inserted into the inflow line. The filtered
and humidified gas is then introduced into the liver by
connecting the tubing to a catheter, previously inserted
into the suprahepatic caval vein. In order to avoid any
kind of barotraumas to the vulnerable hepatovascula-
ture, The applied driving pressure of the gas entering
the liver is limited to 18 mmHg, e.g. by means of an
interposed pressure relief valve.
The liver is continuously placed immerged in cold pre-
servation solution in a beaker, kept cold by surrounding
crush ice (cf. Figure 1).
The infrahepatic caval vein is temporarily closed by
means of a small atraumatic bulldog clamp. After connect-
ing the persufflation catheter to the gas tubing, postsinu-
soidal venules appear to be dilated due to the pressure
applied to the hepatic venous system. Using a small 27
gauge syringe needle, small pinpricks are set into the
dilated venules in all areas at the periphery of the liver
lobes that allow the gas to leave the microvasculature.
After completion of the preparative procedures, sterile
surgical gauze is soaked with the preservation solution and
used to cover the liver during the time of persufflation.
Patients randomized to the control group receive a
liver graft kept simply cold stored until implantation.
Ethical considerations
The responsible physician will inform the patient about
the background and present knowledge on the treatment
protocol under study. It must be emphasized that the
patient is allowed to refuse the treatment at any time prior
to the operation. Before the patient is entered in the study
the patient’s written consent will be obtained. The princi-
pal investigator will ensure that this study will be carried
out in agreement with the “Declaration of Helsinki [22]
and local legal and regulatory requirements. The trial is
monitored by the ZKS Essen according to Standard
Operation Procedures (SOP) that are based on ICH-GCP
guidelines.
An independent safety board monitors closely the
proper conduct of the trial and all SAE reports to ensure
the safety of the subjects during the course of the study.
The study has been approved by the institutional ethi-
cal review committee.
Statistical analyses and data management
The primary endpoint is the maximum absolute AST
value (U/l) on one of the first three post-operative days.
As the AST distribution is highly skewed a non-parametric
statistical procedure, the two-sided exact Mann-Whitney-
U-test, is used for the confirmatory analysis. A SAS Macro
will be used to estimate the relative effect p and to calcu-
late 95% confidence intervals. Though missing data issues
pertaining to the primary endpoint should be minimized
given the continued monitoring during study conduct, the
possibly remaining missing data of the primary endpoint
will be replaced by the maximum global (across both
groups) AST values mimicking a “worst-case scenario”.
The impact of other replacement or imputation strategies
will be analyzed in sensitivity analyses.
The confirmatory analysis will be performed for the
intention-to-treat population (full-analysis set) which
includes all patients randomized for whom transplanta-
tion has been initiated.
In addition, to address the non-parametric Behrens-
Fisher-problem (the sensitivity of the Mann-Whitney-U-
test to any differences in distributions including differences
in variances) and to integrate the stratum variable “MELD-
Score”, sensitivity analyses are preplanned using ANOVA
statistics.
All secondary endpoints (see above) will be analyzed
descriptively as described in the statistics analysis plan.
Data management and statistical analyses will be per-
formed by the Center for Clinical Trials Essen (ZKSE).
Figure 1 Hypothermic reconditioning by gaseous O2-
persufflation. Above: Schematic representation of the persufflated
organ during cold storage on ice Below: Detail of gas bubbles
leaving a human liver through small pin-pricks set into post-
sinusoidal venules.
Minor et al. Trials 2011, 12:234
http://www.trialsjournal.com/content/12/1/234
Page 4 of 6
Adverse events
Any unexpected clinical adverse event or abnormal labora-
tory test value that is serious, including death, occurring
during the course of the study must be reported by the
study coordinator Prof. Minor (Bonn) within 7 days using
the Serious Adverse Event form. The investigator at the
site Essen and Prof. Minor have to assess, if this SAE was
(likely to be) caused by the transplantation and/or oxygen
persufflation. This SAE will be sent to the IEC by Prof.
Minor. The Data Safety Monitoring Board (DSMB) of
OPAL will receive a list of SAE and complication twice a
year. Cases of death will reported without delay to the
DSMB.
Discussion
This clinical trial is based on a long standing series of basic
and translational research including classical mechanistic
in vitro studies as well as in vivo experiments, optimizing
and validating the innovative therapeutic approach of
gaseous oxygen application on a pre-clinical level
[9,11,13,21,23].
After having demonstrated its feasibility in a multi-
case observation [16] it is now intended to establish a
clinical proof of concept on the level of evidence of a
randomized controlled, blinded clinical trial. However,
due to the fact, that the surgeon inevitably gets aware of
the pinpricks during the implantation procedure, it is
not possible to do the trial in a double blinded fashion.
In our opinion it would seems unethical to include sham
pinpricks in the standard procedure, for this would then
no longer be a standard procedure. Moreover, side effects,
however improbable, related to the presence of pin-pricks
would not be as easily be attributed to the treatment
group. We do not think, however, that the lack of blinding
the surgeon will have a notable impact on the primary
endpoint, i.e. the peak level of serum transaminases after
transplantation.
Oxygen persufflation is an attractive adjunct in organ
preservation, seeming particularly suitable in the preser-
vation of the liver, which, unlike other organs, readily
utilizes genuine glycogen as energetic substrate. While
the therapeutic intervention can be postponed to the
immediate pre-implantation period easily performed at
any transplant center, gas persufflation will allow for re-
equilibration of cellular signal and energy homeostasis
and precludes the need of expensive or cumbersome
disposables.
If the present study will confirm the conceptual expec-
tations, a useful method to regenerate cellular energy
dependent pathways in the graft is available to suppress
injurious cellular activation cascades and to improve
postischemic recovery of marginally preserved liver
grafts.
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